Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of β blockers using a new mechanism-based PK-PD modelling approach

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3816-3828

  Van Steeg, T J ^a,b   Boralli, V B ^c   Krekels, E H J ^a   Slijkerman, P ^a   Freijer, J ^b   Danhof, M ^a,b   De Lange, E C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Agonist antagonist interaction; Heart rate; Isoprenaline; Mechanism based; Plasma protein binding NONMEM; Population pharmacokinetic pharmacodynamic modelling; Tachycardia; blockers

Indexed keywords

ATENOLOL; ISOPRENALINE; METOPROLOL; PROPRANOLOL; TIMOLOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PLASMA PROTEIN BINDING; RAT; RECEPTOR AFFINITY; TACHYCARDIA;

EID: 70349255612     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21658     Document Type: Article

References (38)

1. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics - Concepts and applications. Philadelphia, PA, USA: Lippincott Williams & Wilkins.
2. Cox EH, Kerbusch T, Van Der Graaf PH, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: Correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 284:1095-1103. (Pubitemid 28130839)
3. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, 1993. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 33:115-123.
4. Mandema JW, Sansom LN, Dios-VieitezMC, Hollander- Jansen M, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 257:472-478.
5. Van Der Graaf PH, Van Schaick EA, Mathôt RA, Ijzerman AP, Danhof M. 1997. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: Estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816. (Pubitemid 27514643)
6. Black JW, Leff P. 1983. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
7. Kenakin TP. 1993. Pharmacologic analysis of drug-receptor interaction. New York: Lippincott Williams & Wilkins.
8. Van Der Graaf PH, Danhof M. 1997. Analysis of drug-receptor interactions in vivo: A new approach in pharmacokinetic-pharmacodynamic modeling. Int J Clin Pharmacol Ther 35:442-444. (Pubitemid 27462588)
9. Zuideveld KP, Treijtel N, Maas HJ, Gubbens-Stibbe JM, Peletier LA, Van der Graaf PH, Danhof M. 2002. A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino) tetralin-induced hypothermia. J Pharmacol Exp Ther 300: 330-338. (Pubitemid 34028544)
10. Johnsson G, Regardh CG. 1976. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet 1:233-263.
11. Mehvar R, Brocks DR. 2001. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 4:185-200. (Pubitemid 34305610)
12. Riddell JG, Harron DW, Shanks RG. 1987. Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. Clin Pharmacokinet 12:305-320.
13. Singh BN. 2005. Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: An overview. J Cardiovasc Pharmacol Ther 10(Suppl 1):S3-S14.
14. Van Steeg TJ, Freijer J, Danhof M, de Lange ECM. 2007. Pharmacokinetic-pharmacodynamic modeling of S(-)-atenolol in rats: Reduction of isoprenaline- induced tachycardia as a continuous pharmacodynamic endpoint. Br J Pharmacol 151:356-366. (Pubitemid 46842675)
15. Van Steeg TJ, Freijer J, Danhof M, de Lange ECM. 2008. Mechanism-based pharmacodynamic modeling of S(-)-atenolol: Estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. J Pharmacol Exp Ther 324:1234-1242.
16. Belpaire FM, Bogaert MG, Rosseneu M. 1982. Binding of b-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum. Eur J Clin Pharmacol 22:253-256.
17. Rodgers T, Leahy D, Rowland M. 2005. Tissue distribution of basic drugs: Accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 94:1237-1248. (Pubitemid 40904188)
18. Boralli VB, Coelho EB, Cerqueira PM, Lanchote VL. 2005. Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 823:195-202.
19. Beal SL, Sheiner LB. 1999. NONMEM users guide. San Fransisco, CA: University of California at San Fransisco.
20. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Control 19:716-723.
21. Doggrell SA, Petcu EB, Barnett CW. 1998. Affinity constants and beta-adrenoceptor reserves for isoprenaline on cardiac tissue from normotensive and hypertensive rats. J Pharm Pharmacol 50:215-223.
22. Rang H, Dale M, Ritter J. 1999. Pharmacology. Philadelphia: Lippincott.
23. Herve F, Urien S, Albengres E, Duche JC, Tillement JP. 1994. Drug-binding in plasma - A summary of recent trends in the study of drug and hormone-binding. Clin Pharmacokinet 26:44-58. (Pubitemid 24029186)
24. Oie S. 1986. Drug distribution and binding. J Clin Pharmacol 26:583-586.
25. Juberg EN, Minneman KP, Abel PW. 1985. Beta 1-and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol 330:193-202.
26. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. 1999. LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol 367:431-435. (Pubitemid 29106398)
27. Nandakumar K, Bansal SK, Singh R, Bodhankar SL, Jindal DP, Coumar MS, Balaraman R, Bhardwaj SH. 2005. Selective beta(1)-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats. J Pharm Pharmacol 57:515-520. (Pubitemid 40515875)
28. Chiu CC,WuJR, Lee CH, Liou SF, Dai ZK, Chen IJ, Yeh JL. 2004. Anti-hypertension effect of vanylidilol: A phenylaldehyde alpha/beta- adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities. Pharmacology 70:140-151.
29. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R. 1985. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther 235:513-520. (Pubitemid 16248753)
30. Hocht C, Di Verniero C, Opezzo JA, Bramuglia GF, Taira CA. 2006. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: A microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 373:310-318. (Pubitemid 43999782)
31. Wierda JM, Proost JH. 1995. Structure-pharmacodynamic- pharmacokinetic relationships of steroidal neuromuscular blocking agents. Eur J Anaesthesiol Suppl 11:45-54.
32. Danhof M, de Jongh J, de Lange ECM, Della Pasqua PO, Ploeger BA, Voskuyl RA. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400. (Pubitemid 46272134)
33. Tuk B, Danhof M, Mandema JW. 1997. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J Pharmacokinet Biopharm 25:39-62. (Pubitemid 27475326)
34. Tuk B, Herben VM, Mandema JW, Danhof M. 1998. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J Pharmacol Exp Ther 284:202-207. (Pubitemid 28109547)
35. Yassen A, Olofsen E, Dahan A, Danhof M. 2005. Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: Role of receptor equilibration kinetics. J Pharmacol Exp Ther 313:1136-1149. (Pubitemid 40727017)
36. Cleton A, De Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. 1999. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm 27:301-323. (Pubitemid 30136515)
37. Contreras ML, Wolfe BB, Molinoff PB. 1986. Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther 239:136-143. (Pubitemid 16006348)
38. Regardh CG, Ek L, Hoffmann KJ. 1979. Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol - metabolite of metoprolol - in the dog. J Pharmacokinet Biopharm 7:471-479. (Pubitemid 10194533)